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Abstract
Purpose: Retinoblastoma (RB) is a common paediatric intraocular tumour. In the developed world, RB accounts for 
<5% of all paediatric cancers. In the developing world, RB may comprise about 10–15% of all diagnosed paediatric 
cancers according to hospital-based retrospective study in India.
Methods: Medical records for all diagnoses of RB at our regional cancer centre were retrospectively reviewed from 
January 2005 to September 2015 after IRB approval.
Results: A total of 258 (100%) patient charts were reviewed. More male n = 163 (63.2%) patients were seen than 
females n = 95 (36.8%). Most patients were diagnosed before the age of 5 years. Positive family history was seen 
in 20 (7.8%) patients. The total number of bilateral disease was seen in 75 (29.1%) patients and 183 (70.9%) had 
unilateral diagnoses. Median age at presentation was 24 months for bilateral and 36 months for unilateral disease.
Conclusions: The median age at presentation shows a significant delay in the establishment of diagnosis for both 
unilateral and bilateral RB. Compared to western data, there were a higher number of male patients seen. Financial 
constraints, access to primary health care, lack of trained personnel and cultural practices are likely factors, leading to 
delayed presentation and advanced disease state.
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Introduction
Retinoblastoma (RB) is the most common intraocular 
tumour of childhood. It is associated with the RB gene 
mutation. When congenital it is present at birth and 
clinically picked up either during well-child checks or 
at an early age by parents. In cases where the disease 
is sporadic or non-hereditary, it presents in a single eye 
later in life between 3 and 5 years of age. Two-thirds of 
all cases of RB are diagnosed before the age of 2 years 
while 95% of cases are diagnosed before 5 years of age.[1]
The incidence of RB is considered to be constant around 
the world at one case per 15,000–20,000 live births, 
which corresponds to about 9000 new cases every year.[2,3] 
Management of RB has improved over the years. Today, in 
the developed world, the early presentation of disease, access 
to care and advancement in therapy have led to a survival 
rate of >90%.[4,5] In developing countries, these rates are 
lower secondary to different reasons and an important one 
being access to health-care resulting in advanced disease at 
the time of presentation to the oncology service.[6,7]
In the 1950s, the Reese-Ellsworth classification system 
was developed to predict the prognosis after treatment 
with radiation. Now, clinicians are using the International 
Classification of RB (ICRB) to better predict outcomes 
of intraocular RB without the need for external beam 
radiation. The ICRB grading is as follows:
Group A:  Small intraretinal tumours (<3 mm) away from 
foveola and disc.
Group B:  Tumours >3 mm, macular or juxtapapillary 
location, or with subretinal fluid.
Group C:  Tumour with focal subretinal or vitreous seeding 
within 3 mm of tumour.
Group D:  Tumour with diffuse subretinal or vitreous 
seeding >3 mm from tumour.
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Group E:  Extensive RB occupying >50% of the globe with 
or without neovascular glaucoma, haemorrhage 
and extension of tumour to optic nerve or 
anterior chamber.
Disease presentation is varied and can include leukocoria, 
strabismus, proptosis, redness and so on. These symptoms 
can overlap with other ophthalmologic conditions. This 
can delay diagnosis by primary health-care providers in 
developing countries not familiar with RB, a rare but 
common cancer in the eyes of young children. The aim 
of this study is to present our institutional experience of 
treatment and outcome in children with RB seen at a large 
freestanding cancer hospital in Lahore, Pakistan.
Methods
We conducted a retrospective chart review of all patients 
diagnosed with RB at a large regional cancer centre in 
Pakistan between January 2005 and September 2015. 
These patients were accepted into the system after a 
detailed history and examination. Studies done before 
starting treatment included ocular ultrasonography, 
examination under anaesthesia, computed tomography 
or a magnetic resonance imaging, bilateral bone 
marrow biopsy, lumbar puncture, audiometry and 
creatinine clearance. The data collection for this analysis 
included age at presentation, sex, family history of RB, 
clinical presentation, treatment administered, treatment 
compliance and outcome duration of survival.
Results
A total of 258 (100%) patients were treated during the study 
period. Of these, 163 (63.2%) were boys and 95 (36.8%) 
girls [Table 1]. Chart review showed 183 (70.9%) patients 
had unilateral disease while 75 (29.1%) had bilateral 
disease. The median age of diagnosis for bilateral disease 
was 24 months (range, 2–96 months) and 36 months 
(range, 1–132 months) for unilateral disease. >50% of the 
patients were older than 24 months and the oldest age at 
presentation was 11 years.
There were 20 (7.8%) families who reported a positive 
family history for RB. 10 (50%) of these had unilateral 
disease and 10 (50%) had bilateral disease. The 
most common presenting symptoms were leukocoria 
n = 145 (56.2%) and proptosis n = 49 (18.9%). Chart 
review showed that 108 (41.8%) patients were lost to 
follow-up, 47 (18.2%) died and 103 (39.9%) were alive 
at the last follow-up at 2 years. 196 (75.9%) patients were 
treated surgically with an enucleation or exenteration, 
whereas the rest of the 62 (24%) were those that were 
managed with chemotherapy without surgical intervention 
at our institution. Specimens for 163 (63.2%) patients were 
available for pathological review.
Our patients received chemotherapy consisting mainly of 
carboplatin, vincristine, etoposide, cyclophosphamide and 
doxorubicin in addition to enucleation. No facilities for 
cryotherapy, brachytherapy, intravitreal or intra-arterial 
chemotherapy were available to our patients at that time. 
A dedicated genetic counselling service was also not 
accessible to patients.
Discussion
We have presented a freestanding cancer centre’s data 
over a significantly long period of time in Pakistan. There 
is a substantial amount of illiteracy, unfamiliarity and lack 
of awareness to seek treatment for paediatric cancers in 
our setting. Some of the families that do sense a problem 
resort to alternative medicine before realizing the need 
to pursue oncologic care. There is no sex predilection in 
RB, yet we see a male predominance. The patriarchal 
society that exists in our setup can be a reason for this 
observation.[8]
In the developed world, patients present at an early age 
with a multidisciplinary approach formulated at the 
onset of therapy. This results in remarkable survival 
outcome along with vision preservation and reduction in 
enucleation rates. Treatment compliance and follow-up 





Extraocular mass 27 (10.5)
Vision loss 14 (5.4)
Strabismus 12 (4.7)
Others 10 (3.9)
M: F ratio 1.7:1
JOURNAL OF CANCER & ALLIED SPECIALTIES 3
ORIGINAL ARTICLE J Cancer Allied Spec 2017;3(2):3
Follow-up of our patients was inadequate with very 
high rates of treatment abandonment. This is partly due 
to resource-limited setting and potential lifesaving yet 
surgically disfiguring options put forward in cases of 
extraocular disease.
One of the other key issues this study highlights is the 
diagnosis and treatment of paediatric patients with 
RB. The age at presentation is significantly more when 
compared to western data[8-10] subsequently resulting in 
more advanced disease at the time of presentation with 
mostly Group C to E eyes. When there is such progressive 
disease, the primary objective is to save the patient’s life. 
Therapeutic options for globe and vision salvage sans 
enucleation or exenteration are very few.[11,12]
There are institutions in the developed world such as the 
Childhood Eye Cancer Trust and others that promote 
the use of smartphones in detecting a red reflex or the 
presence of a white reflex. The white reflex can be a sign 
of something more serious such as RB. Nowadays, there 
are smartphone applications that help parents and families 
detect a white reflex. These applications enable parents 
detect a white reflex by clicking pictures of their children.
Review of our institutional experience has led us to 
ascertain our practice limitations and consequently 
suggest areas of improvement. First, we need to educate 
families about the signs and symptoms of RB. With the 
widespread availability of smartphones, there is a need 
to educate masses about the use of these devices for the 
detection of a white reflex. The understanding to seek cure 
when children have low-risk disease will result in better 
rates of ocular salvage and sight preservation.[13] As per 
the International Intraocular RB Classification, Group A 
to C eyes are considered amenable to early intervention. 
Primary care providers at the district level in our setup 
should also be trained to recognize such oncologic cases 
earlier and initiate timely referrals. Parents of newborns 
should be advised to get routine eye checkups from 
primary health-care providers.
The second tier of struggle for patients was a gap in 
diagnostic skills and treatment consensus between medical 
care providers and their respective facilities. With the 
development of our freestanding cancer hospital, we 
have implemented a uniform staging workup including 
pathology review and standard treatment guidelines. 
We recommend organizing workshops and teaching 
conferences to help train physicians from other institutions 
who are not familiar with this paediatric diagnosis yet tend 
to see these patients in their practice.
Our team comprises members from paediatric oncology, 
ophthalmology, pathology and radiology responsible for 
discussing new and existing patients with a diagnosis of 
RB in a multidisciplinary meeting.
Conclusions
We encourage our local colleagues to reach out to skilled 
and highly specialized medical professionals for any 
queries about paediatric RB. Our institutional agenda is 
to propagate early detection and attempt optimal local 
tumour control with focal consolidative procedures 
such as laser photocoagulation, cryotherapy and local 
chemotherapy. We are working to introduce intravitreal 
and intra-arterial chemotherapy where possible[14] in early 
disease.
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